StockUS listing USDFTXNASDAQHealthcareCapital Destroyer

Definium Therapeutics, Inc.(DFTX) Stock Analysis | Healthcare

USD --+0.00%
Reward42Moderate
Risk72High
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 3.88Bn
Reward Ratingⓘ42 Moderate reward assessment · 75% data coverage
Bottom 10% of stocksView factors
Risk Ratingⓘ72 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on DFTX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Definium Therapeutics, Inc.?

, a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders.

AI Brief Pro

The brief on Definium Therapeutics, Inc.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Definium Therapeutics, Inc.?

, a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.88B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (42)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta2.209
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
681,951 shares
$3.0M
0
3-6months
558,131 shares
$2.6M
0
6-9months
343,151 shares
$797k
0
9-12months
342,667 shares
$561k
0